Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

NCT ID: NCT00115076

Last Updated: 2021-02-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-08-04
• Study Completion Date: 2011-04-06

Brief Summary

Our laboratory is studying a skin disease known as psoriasis. The purpose of this protocol is to study the action and the effects of Efalizumab, on psoriasis. This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis. The eligible patient will have 10% of his/her body surface area involved with psoriasis vulgaris.

Detailed Description

The eligible patient will receive the drug Efalizumab, weekly for 12 weeks, by injection. The patient will be seen weekly for 12 weeks and every other week for the 12 weeks of follow up. At those visits, the patient can expect that a physical and skin exam will be done. At specific weeks, blood work will be drawn, clinical photography taken and a skin biopsy done. Two types of skin biopsies will be done after local anesthesia has been administered. One is a punch biopsy where a small piece of skin will be taken, the approximate size of a pencil eraser. The second type of skin biopsy is shave biopsy, where a postage sized piece of skin will be taken.

Conditions

Psoriasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

psoriasis

moderate to severe plaque psoriasis

Group Type: EXPERIMENTAL

Efalizumab

Intervention Type: DRUG

24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection

Interventions

Efalizumab

24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection

Intervention Type: DRUG

Other Intervention Names

Raptiva

Eligibility Criteria

Inclusion Criteria

Signed informed consent

• Plaque psoriasis covering >10% of total BSA
• Diagnosis of plaque psoriasis for at least 6 months
• PASI score >=12 (see Appendix A) or Linear PASI score of >= 8.0 at screening (see Appendix B)
• In the opinion of the investigator, candidate for systemic therapy for psoriasis:

• Who has not been previously treated (naive to systemic treatment) OR
• Who has had prior treatment with systemic therapy for psoriasis (e.g., PUVA, cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil (MMF), thioguanine, hydroxyurea, sirolimus, azathioprine, 6-MP, etanercept)
• Body weight of <140 kg
• 18 to 75 years old. As the risk of Efalizumab in childhood is unknown, those < 18years will be excluded from the study
• For women of childbearing potential or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study (while receiving study medication and 3 months following). Acceptable methods of contraception include use of a condom; abstinence; use by sexual partner of oral implantable or injectable contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap; or a sterile sexual partner
• Willingness to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources during the study

Exclusion Criteria

• Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
• History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies or fusion proteins that contain an Ig Fc region
• Clinically significant psoriasis flare during screening or on the first treatment day
• Treatment with efalizumab (anti-CD11a) within the last 12 months before enrollment
• Pregnancy or lactation. As the risk of Efalizumab in pregnancy is unknown, pregnant women will be excluded from the study
• History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
• History of active tuberculosis (TB) or currently undergoing treatment for TB. PPD testing or chest X-ray is required for high-risk subjects (see Appendix D).

Subjects with a positive PPD (not due to BCG vaccination) or chest X-ray will be excluded

• History of opportunistic infections (e.g., systemic fungal infections, parasites)
• Seropositivity for human immunodeficiency virus (HIV)
• Seropositivity for hepatitis B or C virus
• Hepatic enzymes >3 times the upper limits of normal (ULN)
• Diagnosis of hepatic cirrhosis, regardless of cause or severity
• WBC count <4000μL or >14,000/μL
• Serum creatinine >2 times the ULN
• Hospital admission for cardiac disease, stroke, or pulmonary disease within the last year
• Presence of malignancy within the past 5 years, including lymphoproliferative disorders. Subjects with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled
• History of substance abuse within the last 5 years
• Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug Note: Certain medications and vaccines may not be used for specified periods of time prior to enrollment or at any time during the treatment period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

Rockefeller University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

James Krueger, MD

Role: PRINCIPAL_INVESTIGATOR

Rockefeller University

Locations

Rockefeller University

New York, New York, United States

The Rockefeller University

New York, New York, United States

Countries

United States

References

Johnson-Huang LM, Pensabene CA, Shah KR, Pierson KC, Kikuchi T, Lentini T, Gilleaudeau P, Sullivan-Whalen M, Cueto I, Khatcherian A, Hyder LA, Suarez-Farinas M, Krueger JG, Lowes MA. Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs. PLoS One. 2012;7(2):e30308. doi: 10.1371/journal.pone.0030308. Epub 2012 Feb 10.

Reference Type: DERIVED

PMID: 22348003 (View on PubMed)

Other Identifiers

JKR-0511

Identifier Type: -

Identifier Source: org_study_id